Clinical trialNATerminated

Whipple Procedure: Standard of Care vs. Thunderbeat

Thunderbeat™ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Registry Trial

NCT02204124 ↗ ClinicalTrials.gov, retrieved 6 November 2026

Outcome: Stopped earlyPrincipal Investigator and Study Sponsor decided to terminate the study early (Business decision)
Phase: NA
Status: Terminated
Study type: Interventional
Start: 1 January 2015
Expected end: 23 August 2017
Enrollment: 44 participants
Sites: 1
Primary outcomes: Operative Blood Loss; Post-op Morbidity
Sponsor: Other
Results posted: 2018-09-19
Last update: 19 September 2018

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The Whipple procedure is the standard method for therapy for cancerous tumors, inflammation, and stenosis (narrowing) near the head of the pancreas. This is a prospective study to assess whether or not use of the Thunderbeat™ device may decrease blood loss and postoperative morbidity (the presence of illness or disease). The findings will then be compared to patients whose Whipple procedure will be performed using conventional dissection and hemostasis techniques.

Detailed description public domain (ClinicalTrials.gov)

As the pancreas is fed by many vessels, it is necessary to use lots of ligatures, clips and sutures for hemostasis after dissection. This dissection technique is very time consuming and requires numerous changes of instruments. The devices the investigators currently have available for use in the operating suite are EnSeal and LigaSure. A new type of surgical scissors that delivers ultrasonically generated frictional heat energy and electrically generated bipolar energy simultaneously, known as the Thunderbeat™ (Olympus, Japan), is now an available alternative for dissection and hemostasis. Thunderbeat™ was provided FDA clearance in March 2012 for use in open, laparoscopic, and endoscopic surgery, or in any procedure in which cutting, vessel ligation (sealing and cutting), coagulation, grasping and dissection is performed. The Thunderbeat™ device provides the first integration of both bipolar and ultrasonic energies delivered simultaneously from a single multi-functional instrument. This integration provides the surgeon the ability to rapidly cut tissue with ultrasonic energy and to create reliable vessel seals with bipolar energy without having to change devices. The current is provided by a special generator and contains a very high capacity with a low voltage. The body's proteins, such as collagen and elastin, are converted so a permanently sealed zone results. As the tissue between the branches is sealed, lateral thermic tissue damages can be limited to a minimum. Several authors have described a tendency of reduced intraoperative blood loss with bipolar energy devices. Other trials show reduced operating time when a bipolar device is utilized in several surgical procedures, such as thyroid, hepatic, urologic, hemorrhoidectomy and gynecology surgery. Correct dissection in the operating field is very important to avert secondary bleeding or other complications, which might cause re-operation or elevate the patients' morbidity and mortality.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Operative Blood Loss [Day of surgery]. Mean, mL (Standard Deviation). Control Group (n=13): 263.5 (190.0); Thunderbeat™ (n=19): 480.2 (300.5). Analysis, Control Group vs Thunderbeat™: p=0.032; Wilcoxon (Mann-Whitney); superiority.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Post-op Morbidity [Up to 90 days postoperatively]. Count Of Participants, Participants. Control Group (n=13): 7; Thunderbeat™ (n=19): 8. Analysis, Control Group vs Thunderbeat™: p=0.513; Chi-squared; superiority.